Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene hunt aims to unlock secrets of rare heart conditions

NCT ID NCT05330338

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking for new genes that may cause certain types of congenital heart disease, specifically transposition of the great arteries. Researchers will collect DNA from up to 300 children with these heart defects and their parents to find genetic changes. The goal is to better understand the causes of these conditions, which could lead to more personalized care in the future. No new treatments are being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 minute to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with transposition of the great arteries or transposition congenitally corrected of the great arteries with healthy parents and no family history of congenital heart disease (familial trio) * Or patients with transposition of the great arteries or transposition congenitally corrected of the great arteries with or without a history of congenital heart disease (familial form or sporadic case) * Affiliated or beneficiaries of a social security scheme or similar * After obtaining oral consent from patients and/or parents if applicable Parents (for family trios) : \- Biological parents of the child included in the PRECIPED study Exclusion Criteria: * Patients with transposition of the great arteries or transposition congenitally corrected of the great arteries with hypoplastic ventricle or atrioventricular and/or ventriculoarterial valve atresia * Patient with an identified malformation syndrome * Patients under guardianship/curatorship * Patients with State Medical Aid * Refusal of consent by the patient and/or one of the two parents

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart defects, congenital are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congenital heart disease congenitally corrected transposition of the great arteries transposition of the great arteries

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart defects, congenital

Contacts and locations

Locations

  • CHU Angers

    Angers, Maine-et-Loire, 49000, France

  • CHU Bordeaux

    Bordeaux, Gironde, 33000, France

  • CHU Lyon

    Lyon, Rhône, 69000, France

  • CHU Marseille

    Marseille, Bouches-du-Rhône, 13000, France

  • CHU Nancy

    Nancy, Meurthe-et-Moselle, 54000, France

  • CHU Nantes

    Nantes, Loire-Atlantique, 44000, France

  • CHU Rennes

    Rennes, Brittany Region, 35000, France

  • CHU Rouen

    Rouen, Seine-Maritime, 76000, France

  • CHU Toulouse

    Toulouse, Haute-Garonne, 31000, France

  • CHU Tours

    Tours, Val de Loire, 37000, France

  • CHU de Caen

    Caen, Normandy, 14000, France

  • CHU de Lille

    Lille, Hauts-de-France, 59000, France

  • Groupe Hospitalier St Joseph - Hôpital Marie Lannelongue

    Le Plessis-Robinson, Hauts-de-Seine, 92350, France

  • Hôpital Européen Georges Pompidou

    Paris, Paris, 75000, France

  • Hôpital Nord Laennec

    Saint-Herblain, Loire-Atlantique, 44093, France

  • Intercard Lille

    Lille, Nord, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.